Concetta Di Natale, Elena Lagreca, Raffaele Crispino, Roberta D'Auria, Alessandro Attanasio, Rezvan Jamaledin, Raffaele Vecchione, Paolo Antonio Netti
{"title":"Polylactic- Glycolic Acid Microparticles-Encapsulated Prostaglandin E1 as A Novel Strategy In Triple Negative Breast Cancer.","authors":"Concetta Di Natale, Elena Lagreca, Raffaele Crispino, Roberta D'Auria, Alessandro Attanasio, Rezvan Jamaledin, Raffaele Vecchione, Paolo Antonio Netti","doi":"10.1002/open.202500364","DOIUrl":null,"url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is characterized by unique clinical and pathological traits, from which its aggressive nature and the absence of specific treatments are the most worrying. Prostaglandin E<sub>1</sub> (PGE<sub>1</sub>) can affect the morphology of human breast tumor cell lines, but its potential therapeutic effects appear to be counteracted by its high degradability in physiological environments. For this reason, polylactic-glycolic acid polymeric microparticles (MPs) are developed to stabilize PGE<sub>1</sub> in damp conditions and enable sustained local release for the treatment of TNBC after surgical removal of the tumor mass. Specifically, the PGE<sub>1</sub> embedded MPs are produced using a double emulsion solvent-evaporation method, then analyzed through Mastersizer and scanning electron microscopy. Afterward, the encapsulation efficiency and the PGE<sub>1</sub> release are examined using liquid chromatography-mass spectrometry, and their stability at various storage temperatures is assessed. Finally, the carrier toxicity is evaluated in TNBC cells and colon adenocarcinoma epithelial cells, Caco-2. A reliable action on carcinogenic cells specific to breast cancer is observed. Although in vivo studies are still needed, these results open the way to using such a carrier for the intralesional delivery of PGE<sub>1</sub> and its use against TNBC.</p>","PeriodicalId":9831,"journal":{"name":"ChemistryOpen","volume":" ","pages":"e202500364"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemistryOpen","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1002/open.202500364","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Triple-negative breast cancer (TNBC) is characterized by unique clinical and pathological traits, from which its aggressive nature and the absence of specific treatments are the most worrying. Prostaglandin E1 (PGE1) can affect the morphology of human breast tumor cell lines, but its potential therapeutic effects appear to be counteracted by its high degradability in physiological environments. For this reason, polylactic-glycolic acid polymeric microparticles (MPs) are developed to stabilize PGE1 in damp conditions and enable sustained local release for the treatment of TNBC after surgical removal of the tumor mass. Specifically, the PGE1 embedded MPs are produced using a double emulsion solvent-evaporation method, then analyzed through Mastersizer and scanning electron microscopy. Afterward, the encapsulation efficiency and the PGE1 release are examined using liquid chromatography-mass spectrometry, and their stability at various storage temperatures is assessed. Finally, the carrier toxicity is evaluated in TNBC cells and colon adenocarcinoma epithelial cells, Caco-2. A reliable action on carcinogenic cells specific to breast cancer is observed. Although in vivo studies are still needed, these results open the way to using such a carrier for the intralesional delivery of PGE1 and its use against TNBC.
期刊介绍:
ChemistryOpen is a multidisciplinary, gold-road open-access, international forum for the publication of outstanding Reviews, Full Papers, and Communications from all areas of chemistry and related fields. It is co-owned by 16 continental European Chemical Societies, who have banded together in the alliance called ChemPubSoc Europe for the purpose of publishing high-quality journals in the field of chemistry and its border disciplines. As some of the governments of the countries represented in ChemPubSoc Europe have strongly recommended that the research conducted with their funding is freely accessible for all readers (Open Access), ChemPubSoc Europe was concerned that no journal for which the ethical standards were monitored by a chemical society was available for such papers. ChemistryOpen fills this gap.